Approved Product Revenue Stream: Jyseleca (filgotinib) provides an existing revenue stream from its approved status in Europe and Japan, offering financial stability and market validation.

Strong Cash Position: Benefitting from prior strategic collaborations, Galapagos possesses a substantial cash reserve that funds ongoing research and development without immediate reliance on external financing.

Robust R&D Engine: The company has a proven track record of discovering and advancing novel small molecules through various stages of clinical development, particularly in inflammatory and fibrotic diseases.